Evidence map›Paper›PMID 32946880›Full record

ArticleHuman pathology2020

Lack of distinct molecular profile of Primary Dermal Melanoma.

Sheila Shaigany, Basile Tessier-Cloutier, Klaus J Busam, Basil A Horst

Open access · greenAbstract read
In one paragraph

Article in Human pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sheila ShaiganyDepartment of Dermatology, Dermatopathology, Columbia University Medical Center, New York, NY, USA.
Basile Tessier-CloutierDepartment of Pathology and Laboratory Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, USA.
Klaus J BusamDepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Basil A HorstDepartment of Dermatology, Dermatopathology, Columbia University Medical Center, New York, NY, USA; Department of Pathology and Laboratory Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, USA. Electronic address: basil.horst@vch.ca.
Columbia University Irving Medical Center · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Primary dermal melanoma (PDM) is a rare variant of melanoma which simulates metastatic melanoma to the skin. Diagnosis of PDM cannot be established on histologic grounds alone but requires absence of evidence of melanoma elsewhere by clinical history and/or imaging studies. Despite this entity being clinically well documented, limited data on molecular characterization are available. We performed comprehensive mutation and copy number variation analysis in a series of PDMs in search for distinctive molecular features.Studies were approved by respective institutional review boards. Six cases fulfilling strict histologic criteria of PDM were identified in patients with absent history of melanoma elsewhere, negative sentinel lymph node biopsies and imaging studies. DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue, and five cases passed quality control measures and were subjected to targeted exon sequencing using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets 410 panel. Two of five PDM carried NRAS hotspot mutations characteristic of cutaneous melanoma (CM) genomic subtypes. One case showed a probable low-activating NRAS mutation in combination with additional aberrations in other mitogen-activated protein kinase (MAPK) pathway effectors. Hotspot mutations were also identified in the TERT promoter region, and one tumor showed a mutation in the SWI/SNF remodeling complex. No oncogenic mutations were identified in one case. Furthermore, none of the tumors analyzed showed activating mutations in Gα subunits, including GNAQ and GNA11. Copy number alterations included deletions of Chr 9p, characteristic of CM.Despite PDM showing mutational heterogeneity, our findings suggest predominance of MAPK pathway aberrations in agreement with the mutational profile of CMs in general. Given the absence of genetic overlap with other distinct primary dermal melanocytic proliferations, mutational profiling will unlikely aid in the difficult differential diagnosis of PDM versus melanoma metastasis. Thorough metastatic workup remains crucial in establishing this rare diagnosis.

Indexed as

Molecular Diagnostic TechniquesTranscriptomeAdultAgedBiomarkers, TumorBiopsyChromosomal Proteins, Non-HistoneDNA Copy Number VariationsDNA Mutational AnalysisFemaleGene DosageGene Expression ProfilingGenetic HeterogeneityGenetic Predisposition to DiseaseGTP PhosphohydrolasesHigh-Throughput Nucleotide SequencingBiomarkers, TumorChromosomal Proteins, Non-HistoneGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanSWI-SNF-B chromatin-remodeling complexTelomeraseTERT protein, humanTranscription FactorsNext-generation sequencingNRASPrimary dermal melanoma

Identifiers

PMID32946880
PMCPMC8370683
OpenAlexW3087533766

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.